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BACKGROUND: Histone deacetylases (HDACs) are crucial components of the oestrogen receptor (ER) transcriptional complex.
Preclinically, HDAC inhibitors can reverse tamoxifen/aromatase inhibitor resistance in hormone receptor-positive breast cancer. This
concept was examined in a phase II combination trial with correlative end points.
METHODS: Patients with ER-positive metastatic breast cancer progressing on endocrine therapy were treated with 400mg of
vorinostat daily for 3 of 4 weeks and 20mg tamoxifen daily, continuously. Histone acetylation and HDAC2 expression in peripheral
blood mononuclear cells were also evaluated.
RESULTS: In all, 43 patients (median age 56 years (31–71)) were treated, 25 (58%) received prior adjuvant tamoxifen, 29 (67%) failed
one prior chemotherapy regimen, 42 (98%) progressed after one, and 23 (54%) after two aromatase inhibitors. The objective
response rate by Response Evaluation Criteria in Solid Tumours criteria was 19% and the clinical benefit rate (response or stable
disease 424 weeks) was 40%. The median response duration was 10.3 months (confidence interval: 8.1–12.4). Histone
hyperacetylation and higher baseline HDAC2 levels correlated with response.
CONCLUSION: The combination of vorinostat and tamoxifen is well tolerated and exhibits encouraging activity in reversing hormone
resistance. Correlative studies suggest that HDAC2 expression is a predictive marker and histone hyperacetylation is a useful
pharmacodynamic marker for the efficacy of this combination.
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Despite a decrease in incidence, an expected 194280 women will
present with breast cancer in the United States in 2010, resulting in
over 40000 deaths (Jemal et al, 2010). In more than two thirds of
these women, tumours express either oestrogen receptors (ERs) or
progesterone receptors (PgRs), which are frequently less sensitive
to chemotherapy (EBCTCG, 2005), but are amenable to hormonal
therapy. The most commonly used strategies for pharmacological
inhibition of ER signalling are treatment with anti-oestrogens or
aromatase inhibitors. For patients with metastatic disease, the
response rate to first-line hormonal therapy with anti-oestrogens
or aromatase inhibitors ranges from 21% to 33% (Nabholtz et al,
2000; Bonneterre et al, 2001; Mouridsen et al, 2001; Chia et al,
2008). The objective response rates of second-line hormonal
therapies, such as exemestane or fulvestrant, measured by
Response Evaluation Criteria in Solid Tumours (RECIST) criteria
in a recent trial were 6.7% and 7.4%, respectively (Chia et al, 2008).
A study of low dose estradiol as second- or third-line therapy
showed stable disease, but no objective responses (Ellis et al,
2009). Thus, novel approaches to reverse hormone therapy
resistance are needed.
Histone deacetylases (HDACs) and histone acetyltransferases
have important roles in the maintenance and function of
chromatin by regulating the acetylation of histones. Recent data
suggest that HDACs and histone acetyltransferases regulate the
acetylation of many non-histone targets and therefore may
represent a key means of post-translational regulation beyond
their established roles in transcriptional regulation. Biologically,
HDAC inhibitors induce growth arrest, differentiation, and cell
death in breast cancer cells. Despite clinical efficacy in patients
with cutaneous T-cell lymphomas, the therapeutic window of the
currently available HDAC inhibitors may not suffice for mean-
ingful anti-tumour efficacy in breast cancer when used as a single
agent without more careful patient selection or the definition of a
biomarker (Luu et al, 2008).
In preclinical models, treatment of ER-positive breast cancer
cells with HDAC inhibitors leads to transcriptional downregulation
and protein modification of the ER (Yi et al, 2008). Treatment with
an HDAC inhibitor reverses tamoxifen-induced ER stabilisation,
which is followed by induction of pro-apoptotic genes and
apoptotic cell death (Hodges-Gallagher et al, 2006; Bicaku et al,
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s2008; Thomas et al, 2011). Potentiation of tamoxifen by the HDAC
inhibitor vorinostat has been shown in preclinical models at
clinically achievable and tolerable concentrations (Kelly et al, 2005;
Hodges-Gallagher et al, 2006; Galanis et al, 2009; Munster et al,
2009b). Epigenetic modulation of ER signalling by HDAC
inhibitors may therefore represents a novel strategy to reverse
hormone therapy resistance in advanced breast cancer. Further
studies suggest that HDAC1 and 2 may have an important role in
the regulation of oestrogen signalling and may therefore be
relevant targets for HDAC inhibitor activity.
Prior studies with HDAC inhibitors suggest that these agents
have a relatively short terminal half-life, with that of vorinostat
reported to range from 21 to 58min (Kelly et al, 2003). However,
the pharmacodynamic effects often exceed the plasma half-life of
these drugs, suggesting that pharmacodynamic measures may be a
better predictor of tissue drug exposure than pharmacological
values. Furthermore, several studies suggest vorinostat levels vary
considerably between patients (Kelly et al, 2003; O’Connor et al,
2006). This may account for the poor correlation between
vorinostat plasma levels and change in histone acetylation, a
biomarker for molecular response (Munster et al, 2009b). A
pharmacodynamic assay has therefore been developed by our
laboratory to measure histone acetylation and HDAC enzyme
expression in peripheral blood mononuclear cells (PBMCs) to
allow for a more reliable means to measure the target activity of
HDAC inhibitors in this study. Published data from a previous trial
suggest that the change in histone acetylation in in vitro models,
PBMCs, and tumour cells is comparable (Hodges-Gallagher et al,
2006; Bicaku et al, 2008).
Therefore, the objectives of this phase II trial were (1) to
evaluate the toxicity of vorinostat and tamoxifen when adminis-
tered in patients with hormone receptor-positive breast cancer
after progression on prior hormone therapy, (2) to estimate the
anti-tumour activity of vorinostat and tamoxifen in this patient
population, and (3) to characterise the pharmacodynamic profile
of histone acetylation and HDAC2 expression.
MATERIALS AND METHODS
Patient selection
Pre- and post-menopausal women with ER- or PgR-positive
metastatic breast cancer with (1) progression on any number of
aromatase inhibitors for metastatic disease or (2) recurrence of
disease while on adjuvant aromatase inhibitors or (3) pre-
menopausal women who had completed tamoxifen for at least 1
year were eligible for this trial who did not wish to undergo ovarian
suppression in conjunction with aromatase inhibitor treatment.
Prior treatment with tamoxifen or fulvestrant was permitted in the
adjuvant setting, yet not for metastatic disease. Patients were
allowed to have up to three prior chemotherapy regimens for
metastatic disease. Bone-only disease was permissible if at least one
lesion measured 1cm by magnetic resonance imaging. Measurable
disease, as defined by RECIST 1.0, was required. Other eligibility
criteria were (1) Eastern Cooperative Group performance status of 0,
1, or 2; (2) adequate bone marrow function (white blood cell count
X3000 per mm
3, absolute neutrophil count X1500 per mm
3,a n d
platelets X100000 per mm
3), adequate hepatic function (aspartate
aminotransferase, alanine aminotransferase, and alkaline phospha-
tase levels p2.5 times upper limit of institutional normal, total
bilirubin p2.0mgdl
 1), and adequate renal function (serum
creatinine p1.8mgdl
 1 or creatinine clearance 460ml per minute
times upper limit of institutional normal); (3) no prior treatment
with HDAC inhibitors or other therapies for breast cancer within the
preceding 3 weeks, (4) no prior radiation to the only measurable
lesion; (5) no active intercurrent medical condition; (6) no vaginal
bleeding, known endometrial hyperplasia, or cancer; and (7) no
other invasive malignancies within the last 5 years, with the
exception of non-melanoma skin cancer and in situ cervical cancer,
(8) patients with brain metastases had to demonstrate stability for at
least 90 days. Patients with prior thromboembolic events were to be
on therapeutic anti-coagulation during the entire time of study.
All participants provided written informed consent, and
participating institutions obtained annual Institutional Review
Board approval in accordance with federal, state, local, and
institutional requirements and guidelines.
Drug administration, safety, and response assessment
Patients received 400mg of vorinostat once daily for 21 of 28 days
and 20mg tamoxifen daily without interruption. Both drugs were
given in an oral formulation. A cycle consisted of 28 days. Patients
were allowed to remain on treatment until disease progression or the
emergence of unacceptable toxicity. Toxicity assessment, interim
history and physical exams, complete blood count, and serum
chemistry profile chemistries (electrolytes, blood urea nitrogen,
creatinine, magnesium, calcium, phosphate, aspartate aminotrans-
ferase, alkaline phosphatase, and total bilirubin) were obtained at
baseline, weekly in cycle one, and then on day 1 of every cycle.
Tests for tumour markers and documentation of measurable
disease by computed tomography (CT) to evaluate response were
performed after every two cycles. Adverse events and other
symptoms were graded according to the NCI Common Terminol-
ogy Criteria of Adverse Events (CTCAE) version 3.0. Both agents
were given at the full prescribing dose. As this was the first trial to
combine vorinostat with tamoxifen, we performed additional
safety evaluations during the enrolment of the first 15 patients with
the mandate to halt the trial in the case where grade 3 and 4
toxicities were seen in 4 or more of the first 15 patients. A
reduction to 75% of the vorinostat dose was required for patients
experiencing grade 3 non-haematological toxicity and grade 4
haematological toxicity after recovery of toxicities with a second
dose modification to 50%. If toxicities persisted, patients were
withdrawn from the study. Consistent with standard practice, the
tamoxifen dose was reduced for tamoxifen-specific toxicity only.
Pharmacodynamics: histone acetylation and HDAC
expression
Peripheral blood mononuclear cells obtained pre-treatment and
day 8 post-treatment in cycle 1 were isolated by Ficoll centrifuga-
tion (Ficoll-Paque, GE HealthCare, Piscataway, NJ, USA). Cells
were spun onto glass slides, fixed in 5% acetic acid/95% ethyl
alcohol, and blocked with 2% bovine serum albumin. Histone H4
acetylation (rabbit polyclonal, Upstate Biotechnology, Lake Placid,
NY, USA), and HDAC2 (monoclonal, Upstate Biotechnology) were
visualised using fluorescently labelled secondary antibodies. Slides
were counter stained with an antibody control directed against
pan-histone H3 (monoclonal, BD Biosciences, Franklin Lakes, NJ,
USA) for acetyl-H4 and polyclonal, Upstate Biotechnology for
HDAC2) and evaluated by immunofluorescence microscopy (Zeiss
Axio Imager.Z2, Carl Zeiss Inc., Thornwood, NY, USA). Resultant
images were analysed as previously described (Munster et al,2 0 0 7 ,
2009a). Briefly, the mean pixel intensity for each epitope was
determined within the nucleus from acquired images using Adobe
Photoshop software. The mean pixel intensity for each epitope was
determined adjacent to each cell and subtracted from the nuclear
value to control for background staining. Pre- and post-treatment
histone acetylation and HDAC2 expression were normalised to pan-
histone H3 expression (Munster et al, 2007, 2009a). At least 100 cells
were evaluated from two slides for each time point and condition.
Changes in H4 histone acetylation were further verified by western
blot when sufficient sample was available (Munster et al,2 0 0 7 ,
2009a). In brief, total cell extracts (10mg) were separated by SDS–
PAGE and probed with primary antibodies against histone acetyl-H4
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sand pan-histone H3 (polyclonal, Upstate Biotechnology). Protein
levels were quantified by densitometry using Image J software (NIH).
Statistical design and methods
The study employed a Simon two-stage design with early stopping
rules to preempt enrolment in the event of insufficient activity or
excessive toxicity (Chen and Ng, 1998). During the first stage, 18
patients were to be enrolled and evaluated. If at least two responses
were observed among the first 18 patients, an additional 25
patients were to be enrolled in a second phase. The regimen would
be considered inactive if seven or fewer patients responded. If the
‘true’ response probability is 10%, the average probability to end
the trial early would be 73.38%. Conversely, if the ‘true’ response
probability is 25%, there is a 13.53% probability to incorrectly
classify the trial as inactive. Pearson’s correlation coefficient
methods were used to estimate correlations between two variables
and to perform the test of significance of the estimated correlation
with two-sided P-values at a 0.05 significance level (SAS version
9.1, SAS Institute Inc., Cary, NC, USA). Early stopping rules were
set for dose-limiting toxicities to occur in no more than 33% of
patients in the first cycle.
RESULTS
Patient characteristics
The study (clinicaltrials.gov identifier number NCT00365599)
enrolled 43 evaluable patients at the Moffitt Cancer Center in
Tampa, Florida and the University of California, San Francisco.
One patient withdrew consent after 2 weeks and had to be replaced
as pre-specified by the protocol. Patient characteristics and
demographics are listed in Table 1.
Adverse events
A summary of adverse events by CTCAE (version 3.0) for all the
patients is listed in Table 2. As in standard medical practice, dose
reduction for tamoxifen was not performed for any toxicities, but
tamoxifen was stopped in one patient after she developed a
thromboembolic event. Vorinostat was given 21 of 28 days of each
cycle, whereas tamoxifen was given continuously. This schedule
allowed for the distinction between vorinostat toxicities and
toxicities associated with the combination. The predominant
toxicities of vorinostat included fatigue and anorexia, neutropenia,
lymphopenia, and thrombocytopenia. Dose adjustments were made
for all patients with drug-related grade 3 and grade 4 toxicities
associated with vorinostat. Dose adjustments to 300mg vorinostat
for grade 3 toxicities in 13 patients (30%) and to 200mg for grade 4
toxicities or persistent grade 3 toxicities in 7 patients (16%) were
required. These included four (9%) patients requiring dose
reductions for neutropenia as the initial event, four (9%) for
thrombocytopenia, seven (16%) for fatigue, and one each (2%) for
weight loss, liver enzyme elevation, and diarrhoea. Three patients
experienced pulmonary emboli, two of which were incidental
findings on CT scans. One patient had a symptomatic pulmonary
embolus after a long transcontinental flight. In 13 of the 20 patients,
dose reductions were required after the first cycle. Alopecia occurred
in four patients after prolonged exposure (cycle 4þ). Alopecia is
rarely seen with tamoxifen alone, but has been reported in occasional
cases with vorinostat. While a significant number of patients had to
be dose adjusted, another subset tolerated long-term administration
of the drug combination for 2 years or longer.
Anti-tumour efficacy of vorinostat and tamoxifen
Responses were assessed by RECIST criteria version 1.0 (Therasse
et al, 2000). Patients with bone-only disease were required to have
at least one lesion that measured 1cm and was measurable by CT
or magnetic resonance imaging. The study proceeded through the
second stage after confirmed objective responses were seen in 4 of
the first 18 patients, and grade 3 and 4 toxicities in o4 patients.
Confirmed objective responses by RECIST criteria were seen in 8
out of 43 (19%) patients and stable disease for X24 weeks in 9 out
of 43 (21%) patients. Two of the patients with stable disease
showed a complete metabolic response with disappearance of
FGD-PET avidity after an initially increased metabolic activity by
fluoro-deoxy glucose (FDG) positron emission tomogram (PET).
The median number of cycles delivered was four. The time to
progression was 10.3 months (6–30þ months) with an overall
median survival of 29 months (95% confidence interval (95% CI):
20–38.5 months). At the time of this report, two patients remain
on study treatment.
All of the patients with a response or clinical benefit had
progressed on at least one prior aromatase inhibitor, and 8 out of
17 (47%) patients had received prior adjuvant tamoxifen.
Table 1 Patient demographics, tumour characteristics, and treatment
history
Characteristic
Number of patients 43
Measurable disease, n (%) 43 (100%)
Age, median (range), years 56 (33–71)
o65 37 (86%)
465 6 (14%)
Race and ethnicity, n (%)
Caucasian 36 (84%)
Asian 5 (12%)
African American 2 (5%)
Non Hispanic 39 (91%)
Hispanic 4 (9%)
Performance status, median (range) 1 (0–2)
Body mass index, kgm
 2, median (range) 27.9 (20.7–44.2)
Visceral disease, n (%)
Yes 32 (74%)
No 11 (26%)
Hormone receptor status, n (%)
ER+/PR+ 25 (58%)
ER+/PR  17 (40%)
ER+/PR unknown 1 (2%)
ER /PR+ 0 (0%)
HER amplification, n (%)
Amplified 5 (12%)
Non-amplified 38 (88%)
Prior endocrine therapy for metastatic disease, n (%)
0 prior endocrine 3 (7%)
1 prior endocrine therapy 25 (58%)
2 prior endocrine therapies 15 (35%)
Adjuvant endocrine therapy, n (%) 34 (79%)
Tamoxifen 25 (58%)
Aromatase inhibitor 16 (37%)
Aromatase inhibitor for metastatic disease 35 (81%)
Prior chemotherapy for metastatic disease, n (%) 28 (65%)
Regimens: median (range) 1 (0–3)
Cycles delivered, median (range) 4 (1–27+)
Abbreviations: ER¼oestrogen receptor; PR¼progesterone receptor; HER¼human
epidermal growth factor receptor.
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sResponses were seen in patients with or without visceral disease,
and responses were maintained in patients despite the need for
dose adjustments in 8 out of 17 patients. Hormone receptor
expression and prior treatment history of the responders are
depicted in Table 3.
Pharmacodynamics
Previous studies with vorinostat and valproic acid in patients with
solid tumour malignancies suggested that the induction of histone
H4 acetylation in tumour cells was comparable to the increase in
histone H4 acetylation seen in PBMCs (Munster et al, 2007, 2009a).
Similarly, the drug-induced changes in histone acetylation in
tumour and PBMCs mimicked those seen in cultured breast cancer
cells treated with vorinostat at comparable doses. Prior studies
further suggested that the assessment of histone acetylation
required much less tissue or fewer cells when using immuno-
fluorescence and was feasible in tumour tissues obtained by fine
needle administration. Prior studies suggested that histone H4
acetylation was more robust than histone H3 acetylation (Munster
et al, 2007, 2009a). Hence for this study, changes in histone H4
acetylation in PBMCs were measured by immunofluorescence first
and repeated by western blot if sufficient material was available.
Complete pre- and day 8 post-treatment samples were available in
36 out of 43 patients (Figures 1 and 2). Missing data sets were
in part due to the insufficient number of PBMCs as a result of
myelosuppression in a subset of the patients, which happened
early in the course of treatment. The mean increase in histone
H4 acetylation was 20% over baseline and normalised for pan-
histone H3 expression (CI: 14–26%) for the entire group.
In patients with a partial response or stable disease for 424
weeks, the treatment-induced mean change in H4 histone
acetylation was 39% (CI: 26–51%) compared with 10%. In our
experience, the changes in histone acetylation by immunofluores-
cence were typically less pronounced than those seen by western
blot analysis. To confirm the correlation of increased histone
acetylation in responding vs non-responding patients, pre- and
post-treatment samples were assessed for histone acetylation
changes by western blot analysis. Consistent with the immuno-
fluorescence analysis, statistically more pronounced histone H4
acetylation was found in patients with a response or stable disease
(430% increase (CI: 219–633)) vs non-responders (6% (CI:  7–21),
P¼0.042). As seen with our prior studies, the numerical changes
were more robust, the number of patients with no change in
histone acetylation were almost identical. However, immunofluor-
escence requires much less tissue and allows the assessment of
histone acetylation in tumours cells obtained by fine needle
aspiration (data not shown).
While several reports suggest a number of HDAC inhibitor
targets, both histone and non-histone, as relevant for their
observed anti-tumour activity, our preclinical data suggest that
the depletion of HDAC2 by siRNA is sufficient, as its depletion
mimics the effects of an HDAC inhibitor–tamoxifen combination
in vitro. Thus, we believe HDAC2 represents the relevant target for
achieving synergy with tamoxifen. We have further shown that the
select depletion of HDAC2 may be important in the modification
of ER signalling (Bicaku et al, 2008). Similarly, baseline expression
Table 3 Tumour characteristics, prior treatment history, and dose modifications in patients with a response or clinical benefit
Hormone receptor
status
HER2
status
Visceral
disease
Prior aromatase
inhibitors
Prior adjuvant
tamoxifen AC-H4
Dose modification,
mg
Patients with partial response
Patient 1 ER+/PR+ Not ampl Yes Letrozole No Yes
Patient 2 ER+/PR+ Not ampl Yes Anastrozole, exemestane Yes Yes 300
Patient 3 ER+/PR+ Not ampl Yes Anastrozole, exemestane Yes No 200
Patient 4 ER+/PR  Not ampl Yes Letrozole, exemestane No Yes 300
Patient 5 ER+/PR+ Not ampl No Anastrozole No Yes 300
Patient 6 ER+/PR+ Not ampl Yes Letrozole, exemestane Yes Yes
Patient 7 ER+/PR+ Not ampl Yes Anastrozole, exemestane No ND
Patient 8 ER+/PR+ Not ampl No Letrozole No Yes
Patients with stable disease X 24 weeks
Patient 1 ER+/PR  Not ampl No Letrozole, anastrozole Yes Yes
Patient 2 ER+/PR+ Not ampl Yes Letrozole, exemestane, Yes Yes 200
Patient 3 ER+/PR  Not ampl Yes Anastrozole, letrozole No ND
Patient 4 ER+/PR+ Not ampl No Letrozole Yes Yes 200
Patient 5 ER+/PR  Not ampl Yes Anastrozole No Yes
Patient 6 ER+/PR  Not ampl Yes Anastrozole, letrozole No ND
Patient 7 ER+/PR+ Ampl No Letrozole, exemestane No Yes 300
Patient 8 ER+/PR+ Not ampl Yes Letrozole Yes Yes
Patient 9 ER+/PR+ Not ampl No Letrozole Yes Yes 300
Abbreviations: Ampl¼amplified; HER2¼human epidermal growth factor receptor 2; AC-H4¼change in acetyl-H4 expression; ND¼no data; ER¼oestrogen receptor;
PR¼progesterone receptor.
Table 2 Common Terminology Criteria of Adverse Events, grades
(2–4), by number of patients (%)
Grade 2 Grade 3 Grade 4
Non-haematological toxicities (N¼43)
Fatigue 8 (19%) 7 (16%)
Nausea 8 (19%) 2 (5%)
Vomiting 2 (5%) 2 (5%)
Diarrhoea 7 (16%) 1 (2%)
DVT/PE 3 (7%)
Anorexia/weight loss 7 (16%) 4 (9%) —
Mucositis 2 (5%) 1 (2%) —
Hepatic dysfunction (ALT/AST) 3 (7%) 1 (2%) —
Hyperglycaemia 5 (12%) 1 (2%) —
Alopecia 4 (9%) — —
Haematological toxicities (N¼43)
Thrombocytopenia 4 (9%) 3 (7%) 1 (2%)
Leukopenia 4 (9%) 1 (2%) —
Neutropenia 5 (12%) 7 (16%) —
Lymphopenia 5 (12%) 6 (14%) —
Anaemia 2 (5%) — —
Abbreviations: ALT¼alanine aminotransferase; AST¼aspartate aminotransferase;
DVT¼deep-vein thrombosis; PE¼pulmonary embolism.
HDAC inhibitors and tamoxifen for ER-positive breast cancer
PN Munster et al
1831
British Journal of Cancer (2011) 104(12), 1828–1835 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sof HDAC2 was higher in responding vs non-responding patients.
Measured in relative expression to pan-histone H3 expression,
baseline HDAC2 expression in responders (R) was 2.48 times
compared with 1.88 times in non-responders (NR) (P¼0.040,
Figure 2B).
In previous studies, we have shown that the change in histone
acetylation correlates with baseline expression of HDAC2 (Munster
et al, 2007, 2009a) in PBMC and tumour cells. In this study, higher
baseline expression of HDAC2 in PBMCs was associated with a
more pronounced increase in histone H4 acetylation (Figure 3A)
(P¼0.003, Pearson’s correlation coefficient¼0.519).
Dose adjustments were required in 20 (47%) of 43 treated
patients. To determine whether the change in acetylation was
predictive of toxicity, acetylation in patients with grade 3 and 4
toxicities (n¼20) was plotted against acetylation in those with
grade 1 and 2 toxicities (n¼23) only. Changes in acetyl-H4 were
not associated with severity of haematological or non-haematolo-
gical toxicity (P¼0.49, Figure 3B).
DISCUSSION
This is the first clinical study to evaluate the benefits of combining
an HDAC inhibitor with an anti-oestrogen in patients with
advanced ER-positive breast cancer. The rationale for this
combination stems from extensive preclinical data suggesting
epigenetic modulation and post-translational modification of the
ER by HDAC inhibitors enhances the anti-tumour effects of
tamoxifen (Yang et al, 2001; Kawai et al, 2003; Alao et al, 2004;
Jang et al, 2004; Saji et al, 2005; Kawai and Arinze, 2006; Sharma
et al, 2006; Fiskus et al, 2007; Zhou et al, 2007; Bicaku et al, 2008).
We found that treatment of cultured breast cancer cells with
vorinostat leads to downregulation and reversal of tamoxifen-
induced stabilisation of the ER (Bicaku et al, 2008). The anti-
tumour activity of tamoxifen is primarily anti-proliferative. In the
presence of an HDAC inhibitor, however, we find that tamoxifen
induces apoptosis rather than growth arrest. Further studies
suggest that this interaction is mediated through inhibition of
HDAC2 (Munster et al, 2007, 2009b; Bicaku et al, 2008; Marchion
et al, 2009). Select depletion of HDAC2 by small interfering RNAs
mimics the effects of an HDAC inhibitor on the ER and its
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sdownstream signalling (Bicaku et al, 2008). This led us to pursue a
clinical trial evaluating the addition of an HDAC inhibitor to
tamoxifen for the treatment of women with ER-positive breast
cancer who had progressed on prior hormonal therapy.
Vorinostat was the first HDAC inhibitor approved by the FDA
for the treatment of cancer, specifically cutaneous T-cell lymphoma.
In addition to the effects in patients with cutaneous T-cell
lymphoma, HDAC inhibitors appear to be active in Hodgkin’s
lymphoma and other haematological malignancies (Duvic et al,
2007). In contrast, the anti-tumour effects of vorinostat in solid
tumour malignancies have been less evident. Vorinostat has been
tested as a single agent in patients with metastatic breast cancer.
Although disease stabilisation was observed in 30% of the patients,
no clinical responses were achieved (Luu et al, 2008). Similarly,
despite reported efficacy as single agents in several preclinical
models, clinical benefit with HDAC inhibitors in several other solid
tumour malignancies has been modest, limited mostly to disease
stabilisation. Preclinical data from our laboratory and others
suggest that HDAC inhibitors have the ability to re-sensitise
tamoxifen-resistant cells to hormone therapy, and has been
hypothesised to prevent the emergence of hormone therapy
resistance (Yang et al, 2001; Zhou et al, 2007; Thomas et al, 2011).
This study’s findings suggest that the addition of the HDAC
inhibitor vorinostat to tamoxifen results in durable responses
(8 out of 43, 19%) and prolonged disease stabilisation (9 out of 43,
21%) in patients who had progressed on at least one prior
aromatase inhibitor. Further, more than half of the patients had
previously progressed on adjuvant tamoxifen. A significant
proportion of the patients also received chemotherapy. The
expected response rate in this patient population, based on the
EFECT trial, is 7.6% for fulvestrant and 6.7% for exemestane (Chia
et al, 2008). Two more contemporary trials suggested that while
stable disease is achievable, objective, and durable responses are
rare. The first trial reported disease stabilisation, but no objective
responses using estradiol in this setting (Ellis et al, 2009). The
second trial comparing tamoxifen plus placebo vs tamoxifen plus
EGFR inhibitor gefitinib demonstrated that tamoxifen and placebo
treatment resulted in a 15% objective response rate in patients with
newly diagnosed metastatic breast cancer or recurrent disease after
adjuvant tamoxifen. However, in the stratum best comparable to
the patient population in this study, patients recurring on or not
responding to prior aromatase therapy, no objective responses
were observed (Osborne et al, 2011). While in this study, the
observed anti-tumour activity of 19% confirmed partial responses
by RECIST criteria in this heavily pre-treated patient population is
therefore very encouraging. Table 3 shows that responses were
seen in patients after progression on two or three prior endocrine
therapies and chemotherapy.
Furthermore, the correlative studies accompanying this clinical
trial suggest that enrichment of responsive patients may be
feasible. The pharmacological effects of vorinostat were evaluated
in PBMCs. A statistically significant increase in histone H4
acetylation compared with baseline was observed in only 21 out
of 36 (58%) patients (Figure 2). This suggests that 15 out of 36
patients (42% of the evaluated patients) did not reach vorinostat
plasma levels that were high enough to induce a change in histone
acetylation, or did not express the appropriate histone target.
Several studies with vorinostat have shown that histone acetylation
occurs at lower concentrations than those required for the
modulation of other targets. Our data suggest that day 8 histone
acetylation is a strong predictor of response. We have shown
previously that vorinostat-induced histone acetylation in PBMCs is
comparable to histone acetylation in tumour cells (Munster et al,
2009a). The mean increase in histone H4 acetylation for all patients
in this study was 20% (95% CI: 14–26%) over baseline when
treated with 400mg of vorinostat. This may appear lower than has
been previously reported when histone acetylation was measured
by western blot analysis (Kelly et al, 2003). The effects, however,
were comparable to our findings from other studies where histone
acetylation was measured by immunofluorescence. We found that
the observed changes in histone acetylation induced by 400mg
oral vorinostat given daily in this study were comparable to the
results observed in a dose escalation phase I trial evaluating
vorinostat in combination with the anthracycline doxorubicin,
conducted by our group (Munster et al, 2009a). We reported a 25%
increase in mean histone acetylation (95% CI: 3–47) on day 3 in
patients receiving 400mg of vorinostat, with mean plasma levels of
114nM (95% CI: 37–191). Patients treated with higher doses of the
HDAC inhibitor resulted in a 20% increase in median H4 histone
acetylation (95% CI: 29–70) at 600mg of vorinostat, and 84% (95%
CI: 54–114) for 800mg. Corresponding mean vorinostat levels
were 256nM (95% CI: 133–378) and 760nM (95% CI: 598–924),
respectively (Munster et al, 2009a).
To confirm that certain patients did not show a change in
acetylation, we measured histone modification changes alterna-
tively by western blot analysis. Although the range of histone
acetylation measured by western blot analysis was numerically
greater, a significant change in acetyl-H4 was only observed in 57%
of the patients, comparable to the findings of the immunofluor-
escence analysis.
Furthermore, as shown in previous studies, baseline expression
of HDAC2 is positively correlated with a change in histone H4
acetylation (Figure 3A), suggesting HDAC2 is a potential
biomarker and important pharmacological target of vorinostat.
Responders were also more likely to exhibit elevated histone
acetylation following treatment and increased baseline HDAC2
expression (Table 3; Figures 2A and B). An increase in histone
acetylation was observed in 13 of 14 evaluable responders
(Figure 2C). Thus, by identifying hyperacetylators at the initiation
of treatment, patients most likely to benefit from this treatment
would be enriched. Furthermore, determining initial acetylation
response may provide direction for vorinostat dose modification.
Vorinostat and tamoxifen treatment was well tolerated by many
of the patients and long-term exposure of up to 2 years was
feasible. A subgroup of patients required dose modifications,
however, due to grade 3 and 4 toxicities. In addition to
myelosuppression, the predominant toxicities were fatigue and
anorexia. These toxicities have been well described for vorinostat,
and are less likely due to an interaction between vorinostat and
tamoxifen. In the fourth week of each cycle (tamoxifen alone
treatment), patients reported temporary alleviation from nausea,
fatigue, anorexia, and myelosuppression. Notably, dose modifica-
tion did not appear to compromise response, as 8 of the 17 patients
with clinical benefit were dose adjusted, and maintained their
response. Observed toxicities did not correlate with changes in
histone acetylation (Figure 3), suggesting they may be the result of
off target effects.
In support of our preclinical findings, baseline HDAC2
expression in patients’ PBMCs correlated with the degree of
histone acetylation. Thus, the assessment of baseline HDAC2
expression may predict a patient’s molecular response. Patients
with low HDAC2 expression, or those who do not show a change in
acetylation, could then be removed from study or receive higher
doses of the HDAC inhibitor if feasible.
In summary, this trial suggests that the addition of vorinostat to
tamoxifen in patients with hormone receptor-positive breast
cancer results in tumour regression or prolonged disease
stabilisation in 40% of the patients who had progressed on
prior hormonal therapy and chemotherapy. Although the current
study may be limited by its sample size, the results are greater than
those of contemporary studies testing endocrine therapy in
second- and third-line therapy with response rates reported in
o10% of the patients, or no responses when measured by RECIST
criteria (Chia et al, 2008). However, a randomised trial is required
to determine the effects of the combination over the potential
efficacy of tamoxifen alone. Pharmacodynamic assessment of
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at baseline was strong predictors of biological activity and clinical
benefit. This suggests that the absence of histone acetylation could
be used as an early negative predictor for patients who are not
likely to benefit. These patients could then be removed from study,
or be treated with a higher dose. The observed anti-tumour
efficacy warrants further testing of HDAC2 inhibitors and
hormonal therapy, yet the development of rapid acetylation
bioassays and assessment of baseline HDAC2 expression in
tumours in future studies may provide a feasible method to enrich
for patients more likely to benefit.
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